Dealcast 2 November - Italian M&A and ECM activity, Creat/Biotest CFIUS review drags on

episode

Dealcast: The M&A Podcast not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

Finance and Budget Committee - Sep 15, 2026 1h 43m · 15 Sep 2026 · Prince William County Finance and Budget Committee

The Art of True Happiness | Dr. Arthur Brooks 2h 49m · 14 Sep 2026 · Huberman Lab

The Chris Wolfe Podcast: The Power of Quality Supplements 48 min · 14 Sep 2026 · EyeCode Media

NPR News: 09-13-2026 6PM EDT 4 min · 13 Sep 2026 · NPR News Now

Guenther Steiner's 2026 Madrid GP Recap! | Vankah Hours S3E18 1h 11m · 13 Sep 2026 · The Red Flags Podcast

1208: TM Europe win the '26 Solheim Cup 1h 49m · 13 Sep 2026 · No Laying Up - Golf Podcast

Report any issue

Source

Recorded02 Nov 2017

Publisherfast.wistia.com ↗

Handlerec:6530777

Show notes

Dealcast is a fortnightly podcast from the Dealreporter and Activistmonitor teams covering M&A, ECM and activism. The Italian market is put under the microscope in this week's podcast. Dealreporter's Giulia Lasgni tells Julie-Anna Needham that improved sentiment is helping deal and ECM activity. Deane McRobie explains what is slowing down Creat Group's acquisition of Biotest. The US foreign investment committee CFIUS is taking a close look but why has its remit expanded?

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in